Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $5.57

Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $5.57.

A number of equities research analysts have weighed in on the company. Citigroup began coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a "buy" rating and a $5.00 price objective for the company. Wedbush reiterated an "outperform" rating and set a $4.00 price target (down previously from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE acquired a new stake in Mersana Therapeutics in the third quarter valued at $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Mersana Therapeutics in the third quarter valued at about $34,000. China Universal Asset Management Co. Ltd. purchased a new stake in Mersana Therapeutics during the fourth quarter worth about $37,000. Intech Investment Management LLC acquired a new position in Mersana Therapeutics during the third quarter worth about $52,000. Finally, Quarry LP purchased a new position in Mersana Therapeutics in the third quarter valued at about $57,000. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Stock Up 23.6 %

NASDAQ:MRSN traded up $0.12 during midday trading on Wednesday, hitting $0.64. 18,631,841 shares of the company were exchanged, compared to its average volume of 7,823,471. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $6.28. The company has a market capitalization of $79.47 million, a PE ratio of -1.05 and a beta of 1.43. The company has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $1.79.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The business had revenue of $12.60 million for the quarter, compared to analysts' expectations of $7.53 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business's revenue was up 63.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. As a group, equities analysts anticipate that Mersana Therapeutics will post -0.61 earnings per share for the current fiscal year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.